---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-073735"
form_type: "8-K"
ticker: "ADVB"
cik: "0001941029"
company_name: "Advanced Biomed Inc."
filed_at: "2026-06-30T20:34:32+00:00"
generated_at: "2026-06-30T20:35:14.068057+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Advanced Biomed sells Taiwan subsidiary for $490k; retains AI operations

## Summary
- Sale of 100% of Taiwan subsidiary for $490k cash to buyer Miaozhu Zhao.
- Taiwan subsidiary conducts biomedical R&D including A+PerfusC integrated perfusion 3D cell culture platform.
- Company will continue AI-focused operations through Acellent Technologies (Hong Kong) Co. Limited.
- Closing expected within three months from June 30, 2026.

## SEC filing metadata
- accession: 0001213900-26-073735
- form_type: 8-K
- ticker: ADVB
- cik: 0001941029
- company_name: Advanced Biomed Inc.
- filed_at: 2026-06-30T20:34:32+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1941029/000121390026073735/0001213900-26-073735-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1941029/000121390026073735/ea0296529-8k_advanced.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-073735
- JSON: https://secwatch.observer/filing/0001213900-26-073735.json
- Plain text: https://secwatch.observer/filing/0001213900-26-073735.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.